Category:

Antibiotic

Description:

Aminoglycoside antibiotic

Indications:

Serious infections (P. aeruginosa, Proteus species, E. coli, Klebsiella species, Enterobacter species, Serratia species, Citrobacter species, Staphylococcus species)
Bacterial neonatal sepsis
Bacterial septicemia
Serious bacterial infections of the CNS (meningitis)
Urinary tract, respiratory tract, skin, bone and soft tissue (including burns) infections
Gram-negative infections
Emperic therapy for unknown serious infections

Contraindications:

Generally not indicated for long-term therapy due to nephrotoxocity and ototoxicity

Precautions:

Pregnancy category D
May cause nephrotoxicity, therefore closely monitor renal function, especially in elderly patients.
May cause ototoxicity, therefore monitor hearing
Monitor peak and trough serum concentrations
In patients with extensive burns, altered pharmacokinetics may alter serum concentrations.
May produce hypomagnesemia, especially if poor or restricted diet.
Aminoglycosides have neuromuscular blockade activity with a curare-like effect. Monitor patient’s neuromuscular function, especially in patients with myasthenia gravis, parkinsonism or infant botulism.

Adverse Reactions (Side Effects):

Central and peripheral nervous system reactions:
- Headache
- Depression
- Confusion
- Lethargy
- Muscle twitching
- Peripheral neuropathy
Gastrointestinal: vomiting, nausea, anorexia, hypersalivation
Hematologic: changes in reticulocyte counts, anemia, altered WBC counts
Hypersensitivity: rash, urticaria, itching
Special senses: dizziness, tinnitis, vertigo
Renal: oliguria, proteinuria, increased creatinine and BUN
Miscellaneous: apnea, alopecia, joint pain
Pain at injection site
Decreased calcium, sodium, potassium and magnesium levels

Dosage:

Administered by IM or IV injection
Therapy duration is generally 7-10 days

Adults: normal renal function: 3mg/kg/day IV or IM in 3 equal doses every 8 hours
Weight (pounds)	Weight (kg)	Q8 hour Dose (Moderate Infections)
132	60	60 mg IM/IV
154	70	70 mg IM/IV
176	80	80 mg IM/IV
198	90	90 mg IM/IV

Serious infections: 5mg/kg/day divided into 3-4 equal doses
Weight (pounds)	Weight (kg)	Q8 hour Dose (Serious Infections)
132	60	100 mg IM/IV
154	70	117 mg IM/IV
176	80	133 mg IM/IV
198	90	150 mg IM/IV

obese patients:
- base dose on lean body mass
Children:
- 6-7.5mg/kg/day (2-2.5mg/kg q8h)
Infants and neonates
- 7.5mg/kg/day (2.5mg/kg q8h)
Premature or full term neonates (< 1 week of age):
- 5mg/kg/day (2.5mgkg q12h)

Approved for public release; Distribution is unlimited.

The listing of any non-Federal product in this CD is not an endorsement of the product itself, but simply an acknowledgement of the source.

Operational Medicine 2001

Health Care in Military Settings

Bureau of Medicine and Surgery
Department of the Navy
2300 E Street NW
Washington, D.C
20372-5300

Operational Medicine
Health Care in Military Settings
CAPT Michael John Hughey, MC, USNR
NAVMED P-5139
January 1, 2001

United States Special Operations Command
7701 Tampa Point Blvd.
MacDill AFB, Florida
33621-5323

*This web version is provided by The Brookside Associates Medical Education Division. It contains original contents from the official US Navy NAVMED P-5139, but has been reformatted for web access and includes advertising and links that were not present in the original version. This web version has not been approved by the Department of the Navy or the Department of Defense. The presence of any advertising on these pages does not constitute an endorsement of that product or service by either the US Department of Defense or the Brookside Associates. The Brookside Associates is a private organization, not affiliated with the United States Department of Defense.

Operational Medicine 2001 Gentamicin (Garamycin) Injection

Health Care in Military Settings

Operational Medicine 2001
Gentamicin (Garamycin) Injection